Blazing a New Trail

Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class, anti-CD39 antibody.

About Us

Our Science

Our focus is on developing transformational cancer medicines by targeting the mechanisms of immune evasion in the tumor microenvironment. TTX-030, a novel, first-in-class antibody, is currently being studied in phase 1/1b clinical trials.

Learn More

Recent News

November 9, 2023
Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients

April 12, 2022
Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric Cancer/GEJ Cancer

April 4, 2022
Trishula Therapeutics Announces Oral Presentation on TTX-030 Anti-CD39 Antibody at American Association for Cancer Research (AACR) Annual Meeting

More News